Hikma Pharmaceuticals PLC (HKMPF)
OTCMKTS
· Delayed Price · Currency is USD
27.51
0.00 (0.00%)
At close: Mar 10, 2025
Hikma Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 3,127 | 2,875 | 2,517 | 2,553 | 2,341 | Upgrade
|
| Revenue Growth (YoY) | 8.77% | 14.22% | -1.41% | 9.06% | 6.07% | Upgrade
|
| Cost of Revenue | 1,712 | 1,468 | 1,252 | 1,252 | 1,128 | Upgrade
|
| Gross Profit | 1,415 | 1,407 | 1,265 | 1,301 | 1,213 | Upgrade
|
| Selling, General & Admin | 660 | 632 | 601 | 561 | 506 | Upgrade
|
| Research & Development | 141 | 149 | 144 | 143 | 137 | Upgrade
|
| Other Operating Expenses | 20 | 7 | 22 | 36 | 30 | Upgrade
|
| Operating Expenses | 821 | 788 | 767 | 740 | 673 | Upgrade
|
| Operating Income | 594 | 619 | 498 | 561 | 540 | Upgrade
|
| Interest Expense | -93 | -73 | -59 | -43 | -41 | Upgrade
|
| Interest & Investment Income | 8 | 7 | 3 | 1 | 7 | Upgrade
|
| Earnings From Equity Investments | 1 | - | - | 1 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | -3 | -7 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | -14 | -11 | -13 | -11 | Upgrade
|
| EBT Excluding Unusual Items | 510 | 536 | 424 | 507 | 495 | Upgrade
|
| Merger & Restructuring Charges | -11 | - | -41 | - | -3 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1 | 2 | -2 | - | 1 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 12 | -1 | -2 | Upgrade
|
| Asset Writedown | 29 | -85 | -182 | 22 | 33 | Upgrade
|
| Legal Settlements | - | -129 | - | - | - | Upgrade
|
| Other Unusual Items | -74 | -43 | 22 | 16 | 23 | Upgrade
|
| Pretax Income | 455 | 281 | 233 | 544 | 558 | Upgrade
|
| Income Tax Expense | 93 | 89 | 42 | 124 | 128 | Upgrade
|
| Earnings From Continuing Operations | 362 | 192 | 191 | 420 | 430 | Upgrade
|
| Minority Interest in Earnings | -3 | -2 | -3 | 1 | 1 | Upgrade
|
| Net Income | 359 | 190 | 188 | 421 | 431 | Upgrade
|
| Net Income to Common | 359 | 190 | 188 | 421 | 431 | Upgrade
|
| Net Income Growth | 88.95% | 1.06% | -55.34% | -2.32% | -11.32% | Upgrade
|
| Shares Outstanding (Basic) | 221 | 221 | 224 | 231 | 236 | Upgrade
|
| Shares Outstanding (Diluted) | 223 | 222 | 225 | 233 | 238 | Upgrade
|
| Shares Change (YoY) | 0.51% | -1.13% | -3.47% | -2.10% | -2.06% | Upgrade
|
| EPS (Basic) | 1.62 | 0.86 | 0.84 | 1.82 | 1.83 | Upgrade
|
| EPS (Diluted) | 1.61 | 0.85 | 0.84 | 1.81 | 1.81 | Upgrade
|
| EPS Growth | 89.41% | 1.19% | -53.51% | -0.22% | -9.45% | Upgrade
|
| Free Cash Flow | 399 | 439 | 392 | 493 | 292 | Upgrade
|
| Free Cash Flow Per Share | 1.79 | 1.97 | 1.74 | 2.12 | 1.23 | Upgrade
|
| Dividend Per Share | 0.800 | 0.720 | 0.560 | 0.540 | 0.500 | Upgrade
|
| Dividend Growth | 11.11% | 28.57% | 3.70% | 8.00% | 13.64% | Upgrade
|
| Gross Margin | 45.25% | 48.94% | 50.26% | 50.96% | 51.82% | Upgrade
|
| Operating Margin | 19.00% | 21.53% | 19.79% | 21.97% | 23.07% | Upgrade
|
| Profit Margin | 11.48% | 6.61% | 7.47% | 16.49% | 18.41% | Upgrade
|
| Free Cash Flow Margin | 12.76% | 15.27% | 15.57% | 19.31% | 12.47% | Upgrade
|
| EBITDA | 766 | 791 | 670 | 718 | 654 | Upgrade
|
| EBITDA Margin | 24.50% | 27.51% | 26.62% | 28.12% | 27.94% | Upgrade
|
| D&A For EBITDA | 172 | 172 | 172 | 157 | 114 | Upgrade
|
| EBIT | 594 | 619 | 498 | 561 | 540 | Upgrade
|
| EBIT Margin | 19.00% | 21.53% | 19.79% | 21.97% | 23.07% | Upgrade
|
| Effective Tax Rate | 20.44% | 31.67% | 18.03% | 22.79% | 22.94% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.